Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.04 -0.10 (-0.17%)
Official Closing Price Updated: 7:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
31 32 Next >
Why Bristol Myers Squibb Is a Table-Pounding Buy
Value investors can take advantage of the huge discrepancy between the company's valuation and its fundamentals. 
Via The Motley Fool
Bristol Myers' Mavacamten Added Via $13B Myokardia Buyout, Hit By FDA Delay
Bristol Myers Squibb & Co (NYSE: BMY) has announced that the FDA has extended the decision date for mavacamten. Bristol Myers announced that the date has slid... 
Via Benzinga
Exposures Product Safety
What 5 Analyst Ratings Have To Say About Bristol-Myers Squibb
Over the past 3 months, 5 analysts have published their opinion on Bristol-Myers Squibb (NYSE: 
Via Benzinga
2 Dividend Stocks to Buy Right Now
These two drugmakers have a solid track record. 
Via The Motley Fool
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack... 
Via Benzinga
Expert Ratings For Bristol-Myers Squibb
Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings wit... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
Berkshire Exited Merck Before COVID Pill Boost; Trimmed Holdings In AbbVie, Bristol Myers In Q3
Warren Buffett's Berkshire Hathaway Inc (NYSE: BRK-A) cleared its stake in Merck & Co Inc (NYSE: MRK) in Q3, right on the eve of a significant stock... 
Via Benzinga
Tuesday Market Overview
While gold gained modestly again today, cryptocurrencies fell hard. 
Via Talk Markets
Warren Buffet Takes A Stake In Royalty Pharma And Exits Merck — What You Need To Know
Warren Buffet's Berkshire Hathaway added more than 13 million shares. 
Via Investor's Business Daily
Bristol Myers Squibb, Janssen Move Closer To Phase 3 For Blood Thinner Candidate
Bristol Myers Squibb & Co (NYSE: BMY) and Johnson & Johnson's (NYSE: JNJ) unit Janssen Pharmaceuticals Inc announced results from the... 
Via Benzinga
Warren Buffett Stocks: Berkshire Hathaway To Reveal Q3 Stock Buys And Sells
Berkshire Hathaway will file its 13-F, detailing changes to its stock holdings. 
Via Investor's Business Daily
Bristol Myers Rolls Out Long-Term Data For Mavacamten In Heart Disease
Bristol Myers Squibb & Co (NYSE: BMY) has announced long-term data from a mavacamten study acquired via a $13 billion MyoKardia buyout. Heart patients... 
Via Benzinga
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
Bristol-Myers Squibb Q3 Earnings: What Investors Should Know
The stock has underperformed the market over the long term. 
Via The Motley Fool
Better Buy: Bristol Myers Squibb vs. Merck
Which pharma giant is right for you? 
Via The Motley Fool
Exposures COVID-19
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products. 
Via Talk Markets
Why Compugen Surged 14% Higher on Thursday
The company is deepening its partnership with Bristol Myers Squibb. 
Via The Motley Fool
Schrödinger Shares Fall After Q3 Miss, Narrowed FY21 Revenue Outlook
Schrödinger Inc (NASDAQ: SDGR) posted Q3 sales of $29.9 million, +16% Y/Y, missing the consensus of $31.58 million. Software revenue was $24.3 million, +6%... 
Via Benzinga
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &... 
Via Benzinga
3 Rock-Solid Healthcare Dividend Stocks Now on Sale
Now may be a good time to buy these healthcare dividend giants. 
Via The Motley Fool
Bristol Myers' Opdivo Combo Meets Endpoint Goal In Lung Cancer Trial
Bristol Myers Squibb & Co (NYSE: BMY) has announced topline data from Phase 3 CheckMate -816 trial in patients with resectable stage IB to IIIA non-small cell... 
Via Benzinga
Is Bristol Myers Squibb's Reported Acquisition of Aurinia a Smart Move?
It could be. 
Via The Motley Fool
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
3 No-Brainer Biotech Stocks to Buy in November
Here are three Motley Fool contributors' top picks. 
Via The Motley Fool
Here's Why Bristol Myers Squibb Can't Miss Out on Aurinia Pharmaceuticals
The biopharma's takeover bid has failed to materialize after nearly two weeks. Here's what might be going on. 
Via The Motley Fool
Bristol Myers Squibb Just Got Some Great Regulatory News
Bristol Myers Squibb's multiple sclerosis drug Zeposia could soon be approved in the EU to treat ulcerative colitis. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Here's My Top Value Stock To Buy Right Now
EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications. 
Via Talk Markets
New Data Reaffirms Merck's Keytruda In Extending Survival In Melanoma Patients
Merck & Co Inc (NYSE: MRK) announced new data from studies evaluating Keytruda (pembrolizumab) in melanoma patients. The Company shared the data at the... 
Via Benzinga
3 Pharma Stocks You Can Buy and Hold Forever
These drugmakers are built to last. 
Via The Motley Fool
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.